Zheng, Jiaojiao
Santoni, Giola
Xie, Shao-Hua
Lagergren, Jesper
Funding for this research was provided by:
China Scholarship Council (201700260292)
Cancerfonden (190043, 180684)
Vetenskapsrådet (2019-00209)
Article History
Received: 9 November 2020
Revised: 7 April 2021
Accepted: 15 April 2021
First Online: 10 May 2021
Ethics approval and consent to participate
: The study was conducted in accordance with the “Declaration of Helsinki”, and was approved by the Regional Ethical Review Board in Stockholm (2018/271-32). No individual informed consent was needed according to the Swedish regulation.
: Not applicable.
: All the data were retrieved from t<i>he Swedish Prescribed Drugs and Health Cohort</i>. The original data are available from the registries listed above, but restrictions apply to the availability of these data, which were used under license for the current study and therefore are not publicly available. Data may however be available through applications to these registries or reasonable request to the corresponding author (S.X.). The codes for the data analysis are archived by the first author (J.Z.).
: The authors declare no competing interests.
: This work was supported by the Swedish Cancer Society (grant number 180684 to J.L. and 190043 to S.X.); and the Swedish Research Council (grant number 2019-00209 to J.L.). J.Z. receives a scholarship from China Scholarship Council (student number 201700260292). The founding resources were not involved in the study design, data collection, data analysis and interpretation of the results; nor in the writing of the report; and in the decision to submit the article for publication.